5
Participants
Start Date
June 28, 2021
Primary Completion Date
June 1, 2022
Study Completion Date
June 1, 2022
Adavosertib
Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
Itraconazole
Patients will receive Itraconazole orally once daily for 7 days in arm A.
Rifampicin
Patients will receive Rifampicin orally once daily for 13 days in arm B.
Omeprazole
Patients will receive Omeprazole orally once daily for 5 days in arm C.
Research Site, Madrid
Research Site, Málaga
Research Site, Dallas
Research Site, Austin
Research Site, Portland
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY